Anxiety and dysautonomia symptoms in patients with a Na V 1.7 mutation and the potential benefits of low-dose short-acting guanfacine.
Rita de Cássia CollaçoMaxime LammensCarley BlevinsKristen RodgersAndrei GurauSuguru YamauchiChristine KimJeannine ForresterEdward LiuJinny HaYuping MeiCorrine BoehmElizabeth WohlerNara SobreiraPeter C RoweDavid ValleMalcolm V BrockFrank BosmansPublished in: Clinical autonomic research : official journal of the Clinical Autonomic Research Society (2023)
1.7 or other channel subtypes. In a broader context, expanding genetic and functional data about ion channel aberrations may enable the prospect of stratifying patients in which mutation-induced increased sympathetic tone normalization by guanfacine can support treatment strategies for anxiety and dysautonomia symptoms.
Keyphrases
- low dose
- sleep quality
- end stage renal disease
- ejection fraction
- newly diagnosed
- copy number
- prognostic factors
- peritoneal dialysis
- high dose
- high glucose
- genome wide
- electronic health record
- gene expression
- depressive symptoms
- big data
- physical activity
- oxidative stress
- diabetic rats
- endothelial cells
- patient reported